Company Overview
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Recent Developments
- Dec 2025 Revenue of $1.12M (+2511.6% YoY); net profit $-11.17M.
- Trailing 12 Months Year-on-year growth — revenue +115.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 115.40% |
Stock Price Performance
| 1 Year: | +80.33% |
| 6 Months: | +175.00% |
| 3 Months: | +148.31% |
| 1 Month: | +96.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)70.17 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNXT RenovoRx, Inc. PHARMA | 2.20 | -7.10 | $99.28M | 0.00% | - | -125.23% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 197.00K | 422.00K | 266.00K | 238.00K | 563.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.00K | 152.00K | 53.00K | 28.00K | 84.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 103.00K | 270.00K | 213.00K | 210.00K | 479.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.21M | 2.95M | 3.41M | 3.73M | 3.95M |
| Operating Income | - | - | -910.00K | -1.05M | -866.00K | -1.40M | -3.00M | -2.61M | -2.16M | -3.26M | -3.38M | -2.98M | -2.48M | -3.03M | -2.83M | -3.11M | -2.68M | -3.20M | -3.52M | -3.47M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.11M | -2.68M | -3.20M | -3.52M | -3.47M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.42M | -2.90M | -2.91M | -2.94M | -3.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.05M | -773.00K | -1.10M | -1.15M | -1.31M | -1.51M | -3.00M | -2.59M | -2.14M | -3.26M | -2.33M | -1.42M | -1.08M | -2.39M | -2.47M | -2.42M | -2.90M | -2.91M | -2.94M | -3.52M |
| Diluted EPS | - | - | - | - | - | - | - | -0.29 | -0.24 | -0.36 | -0.22 | -0.13 | -0.07 | -0.10 | -0.10 | -0.08 | -0.08 | -0.08 | - | -0.09 |
| R&D Expense | - | - | 727.00K | 635.00K | 536.00K | 767.00K | 1.29M | 1.39M | 846.00K | 1.34M | 1.93M | 1.63M | 1.26M | 1.54M | 1.65M | 1.64M | 1.43M | 1.69M | - | 1.23M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 43.00K | 1.12M |
| Cost of Revenue | - | - | - | 0 | 0 | 327.00K |
| Gross Profit | - | - | - | 0 | 43.00K | 796.00K |
| Operating Expenses | - | - | 9.95M | 11.40M | 11.01M | 13.31M |
| Operating Income | -3.20M | - | -9.95M | -11.40M | -10.97M | -12.51M |
| EBITDA | - | - | -9.94M | -11.40M | -10.97M | -12.51M |
| Interest Expense | - | 834.00K | - | - | - | - |
| Pretax Income | - | - | -9.89M | -10.23M | -8.81M | -11.17M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -3.80M | - | -9.89M | -10.23M | -8.81M | -11.17M |
| Diluted EPS | - | - | -1.09 | -0.99 | -0.40 | -0.32 |
| R&D Expense | 2.39M | 3.04M | 4.30M | 5.67M | 6.03M | 6.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.91M | - | 7.26M | 1.47M | 8.12M | 8.10M |
| Current Assets | - | - | - | 7.26M | 1.47M | 7.83M | 7.89M |
| Cash & Equivalents | - | 1.79M | - | 4.39M | 1.17M | 7.15M | 7.02M |
| Inventory | - | - | - | - | - | 0 | 189.00K |
| Receivables | - | - | - | - | 0 | 43.00K | 139.00K |
| Total Liabilities | - | 4.12M | - | 1.10M | 4.47M | 3.64M | 2.67M |
| Current Liabilities | - | 4.10M | - | 1.10M | 1.18M | 1.91M | 1.96M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 0 | 278.00K | 212.00K |
| Total Equity | -10.93M | -14.66M | - | 6.16M | -3.00M | 4.48M | 5.42M |
| Shares Outstanding | - | - | - | 9.10M | 10.69M | 24.03M | 36.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.53M | - | -8.81M | -10.26M | -9.12M | -10.97M |
| Investing Cash Flow | - | - | -2.03M | 2.03M | -12.00K | -2.00K |
| Financing Cash Flow | 3.20M | - | 42.00K | 5.01M | 15.12M | 10.85M |
| Capital Expenditure | - | -15.00K | - | - | -12.00K | -2.00K |
| Free Cash Flow | - | - | -8.81M | -10.26M | -9.14M | -10.97M |
| Net Change in Cash | - | - | -10.80M | -3.22M | 5.98M | -130.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 100.0% | 70.9% |
| Operating Margin % | - | - | - | - | -25,511.6% | -1,114.1% |
| Net Margin % | - | - | - | - | -20,497.7% | -994.5% |
| ROE % | 25.9% | - | -160.5% | 341.1% | -196.8% | -206.0% |
| ROCE % | 146.8% | - | -161.4% | -3,916.2% | -176.7% | -204.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 9.76% | 4.41M | $7.45M |
| 2 | Bleichroeder LP | 3.69% | 1.67M | $2.82M |
| 3 | Vanguard Capital Management LLC | 3.20% | 1.44M | $2.44M |
| 4 | Geode Capital Management, LLC | 0.94% | 424.15K | $716.81K |
| 5 | Wealthspire Advisors, LLC | 0.56% | 252.53K | $426.77K |
| 6 | Vanguard Fiduciary Trust Co | 0.53% | 240.33K | $406.16K |
| 7 | Citadel Advisors Llc | 0.30% | 133.60K | $225.78K |
| 8 | Chicago Partners Investment Group LLC | 0.20% | 92.36K | $156.08K |
| 9 | Northern Trust Corporation | 0.19% | 85.21K | $144.00K |
| 10 | Northwestern Mutual Wealth Management Company | 0.17% | 74.60K | $126.07K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNXT
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1JVzNOTmJOdG90Z3Byc0lHRzZyOUF4dHI5ekFMVU1jYjYweXZlZE16Y0hzaUo1NU5CVEtCTmlCZE1fTTlsZWFXbw?oc=5" target="_blank">Renovorx Stock Price Forecast. Should You Buy RNXT?</a> <f…
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQc3V3VmxuckxtN2lnbkpEWGdDQUExSlFXeEF1ZXNkWGRZa3lKWGNKdnJIaV91U3N4U0FSX05CTGtrUjhCZzVFSTNoT09XVTc1b212N21ObUV6Q0NXb0hMenRsQmg5U3UwQWJSRENmX25xYU4yeDJ2TTJFdHlDdGpPbkRCbDZscVNtV0djRF…
RenovoRx’s cancer drug-delivery device now has 20 issued or allowed patents - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPOWxXRS03dEI4cVVBZWUxS1JLRjdxRVVoSlM1TTBHYXpPdjk3T09JY0R0R2VLQzFmLVh2RmpINWJ5dng3blR1bWNRc0dYbGpsNmc0a29DRG1YN1BYSjg3UTR1OEZ3Wl9Ja1ZrQjhsaWtDVkJ4S29xbzUwTDNVa3dlVi1mbU9pWDRNQS1LN3…
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPOUhJZF9oYVd3ZERRT2ZnU0NRWXZXNy1LczByamlxVFYwWjdoeTZnN0VZa1dfdEsxWlZCdWZWb0hTTXNYajVZbmJMUjdITV9SbGV5LXdydjBLTGo2dENYM2NOc0k5X0loQ2JKTXgwc0w2NVZ4ZGt5TWFuVXRIQzhHN0V6ZU5ZWXh6eDQ4eV…
RNXT Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9WTDRHV3htbmR5TzlmOTFqS09udWIwaE1EWHQwcHU2ejRqaTJQcVoyc2lneW0wVEMyaGh5VHRjaEkxV3RGLVB2N2lUVTItMkxIeEFHSHo4eHRVeHNFYmF6VHdzZDBhOW12ZWVCYXBjbFotN0V6ZjFBRGhR?oc=5" target="_blank">RNX…
$RenovoRx (RNXT.US)$ - Moomoo
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9hRVRFSFBGN0xiMko2cUItc2Y4UnNiSk1qWktLREoyVmlWZDh2VzR2OG5kTmR0cU1iRE1ZM0xhQ1JJbkVYeVg2NXRwV2lvSVcxWktvbzdyMUliTFBXdXFoQkFTMTYta1lZZHR1UmhlWlpUbVFYeDJnQnlR?oc=5" target="_blank">$Re…
RNXT — Frequently Asked Questions
What is the current share price of RenovoRx, Inc. (RNXT)?
As of 2026-09-19 21:16 PDT, RenovoRx, Inc. (RNXT) trades at $2.20 on NasdaqCM. Its 52-week range is $0.73 to $2.52.
What is the market capitalisation of RNXT?
RenovoRx, Inc. (RNXT) has a market capitalisation of $99.28M on NasdaqCM.
What is the P/E ratio of RNXT?
RNXT trades at a trailing price-to-earnings (P/E) ratio of -7.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.49.
What is the return on equity (ROE) of RNXT?
RNXT has a return on equity (ROE) of -125.23%.
Is RNXT a good stock to buy?
This page provides a data-driven analysis of RenovoRx, Inc. (RNXT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.